Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir

Mindie H. Nguyen, Masanori Atsukawa, Toru Ishikawa, Satoshi Yasuda, Keisuke Yokohama, Huy N. Trinh, Taeang Arai, Shinya Fukunishi, Eiichi Ogawa, Yao Chun Hsu, Mayumi Maeda, Hansen Dang, Cheng Hao Tseng, Hirokazu Takahashi, Dae Won Jun, Tsunamasa Watanabe, Makoto Chuma, Akito Nozaki, Norifumi Kawada, Ramsey CheungMasaru Enomoto, Koichi Takaguchi, Hidenori Toyoda

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


INTRODUCTION:Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96 weeks after ETV-to-TAF switch.METHODS:ETV-treated (≥12 months) chronic hepatitis B patients switched to TAF in routine practice at 15 centers (United States, Korea, Japan, and Taiwan) were included. Primary outcome was complete viral suppression (CVS) rate (HBV DNA <20 IU/mL).RESULTS:We analyzed 425 eligible patients (mean age 60.7 ± 13.2 years, 60% men, 90.8% Asian, 20.7% with diabetes, 27% with hypertension, 14.8% with cirrhosis, 8.3% with hepatocellular carcinoma, and mean ETV duration before switch 6.16 ± 3.17 years). The mean baseline estimated glomerular filtration rate (eGFR) was 89 ± 19 (chronic kidney disease [CKD] stages: 55.6% stage 1, 35.7% stage 2, and 8.8% stages 3-5). CVS rate increased from 91.90% at switch (from 90.46% 24 weeks before switch) to 95.57% and 97.21% at 48 and 96 weeks after (P = 0.03 and 0.02, respectively). Over the 96 weeks after switch, mean HBV DNA (P < 0.001) but not alanine aminotransferase or CKD stage decreased. Between switch and 96-week follow-up, 11% (26/235) of CKD stage 1 patients migrated to stage 2 and 8% (12/151) of stage 2 patients to stages 3-5, whereas 18% (27/151) from stage 2 to 1, and 19% (7/37) from stages 3-5 to 2. On multivariable generalized estimated equation analysis adjusted for age, sex, hypertension, diabetes, and cirrhosis, baseline eGFR, age (P < 0.001), and CKD stages 2 and 3-5 (vs 1) (both P < 0.001) were associated with lower follow-up eGFR.DISCUSSION:After an average of 6 years on ETV, CVS increased from 91.9% at TAF switch to 97.2% at 96 weeks later.

Original languageEnglish
Pages (from-to)1264-1273
Number of pages10
JournalAmerican Journal of Gastroenterology
Issue number6
Publication statusPublished - Jun 1 2021

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir'. Together they form a unique fingerprint.

Cite this